Company Profile
Pyxis Oncology Stock Price, News & Analysis
- Ticker:
- PYXS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.75 USD (+19.81%)
Close
Last updated: August 6, 2026
108M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, PYXS closed up 19.8% at $3.75. No new same-company headline was identified in the current news window.
Company overview
Tumor-Microenvironment ADC Company
Pyxis Oncology develops antibody-drug conjugates for difficult-to-treat cancers, with a strategy that targets structural components of the tumor microenvironment.
MICVO
Micvotabart pelidotin, or MICVO, targets extradomain-B fibronectin, a non-cellular component enriched in tumor tissue. This approach is intended to deliver a cytotoxic payload across heterogeneous tumors without relying on uniform tumor-cell antigen expression.
Head and Neck Cancer Focus
MICVO is being evaluated as monotherapy in previously treated recurrent or metastatic head and neck squamous cell carcinoma and with pembrolizumab in the first-line setting.
Future catalysts
Updated Phase 1 MICVO monotherapy data in second-line or later head and neck cancer are expected around mid-2026.
Updated Phase 1/2 data for MICVO plus pembrolizumab in first-line recurrent or metastatic head and neck cancer are expected in the second half of 2026.
Recent news
- 01
- 02
- 03
Pyxis Oncology to Participate in Upcoming Investor Conferences
Source: Pyxis Oncology
- 04
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
Source: Pyxis Oncology
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Pyxis Oncology (PYXS)?
Pyxis Oncology (PYXS) most recently closed at 3.75 USD, a +19.81% move versus the previous session.
What is the market cap of Pyxis Oncology (PYXS)?
Pyxis Oncology currently has a market capitalization of 108M USD on BioPharmSignal.
What does Pyxis Oncology do?
Tumor-Microenvironment ADC Company Pyxis Oncology develops antibody-drug conjugates for difficult-to-treat cancers, with a strategy that targets structural components of the tumor microenvironment. MICVO Micvotabart pelidotin, or MICVO, targets extradomain-B fibronectin, a non-cellular component enriched in tumor tissue. This approach is intended to deliver...
On which exchange is PYXS stock listed?
Pyxis Oncology (PYXS) is associated with NASDAQ, United States, Biopharma.
What is pembrolizumab?
Updated Phase 1/2 data for MICVO plus pembrolizumab in first-line recurrent or metastatic head and neck cancer are expected in the second half of 2026.
Which conditions is Pyxis Oncology targeting with pembrolizumab?
Pyxis Oncology is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Pyxis Oncology describe recent progress with pembrolizumab?
Updated Phase 1/2 data for MICVO plus pembrolizumab in first-line recurrent or metastatic head and neck cancer are expected in the second half of 2026.
What is Tumor-Microenvironment?
Tumor-Microenvironment ADC Company Pyxis Oncology develops antibody-drug conjugates for difficult-to-treat cancers, with a strategy that targets structural components of the tumor microenvironment.